GeneFerm Biotechnology Co

GeneFerm Biotechnology Co Gross Margin

The Gross Margin of GeneFerm Biotechnology Co (1796.TWO) as of Nov 5, 2026 is 28.18 %. In the previous year, Gross Margin was 18.56 % — a change of 51.80% (higher).

Gross Margin

28.18 %

YoY

51.80%

Last updated:

Gross Margin of GeneFerm Biotechnology Co is 2025 28.18 % . Gross Margin of GeneFerm Biotechnology Co was 2024 18.56 % . It decreases by 51.80% higher compared to the previous year.

For GeneFerm Biotechnology Co, the gross margin of 28.2% is down versus 36.9% a few years ago.

The GeneFerm Biotechnology Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
32.99 TWD
Jan 1, 2019
23.62 TWD
Jan 1, 2020
33.12 TWD
Jan 1, 2021
36.88 TWD
Jan 1, 2022
35.04 TWD
Jan 1, 2023
36.07 TWD
Jan 1, 2024
18.56 TWD
Jan 1, 2025
28.18 TWD
The GeneFerm Biotechnology Co Gross Margin history
YEARGross MarginYoY
28.18 %+51.80%
18.56 %-48.54%
36.07 %+2.94%
35.04 %-4.99%
36.88 %+11.36%
33.12 %+40.21%
23.62 %-28.40%
32.99 %-21.99%
42.29 %-15.39%
49.98 %+23.38%
40.51 %+46.13%
27.72 %+7,545.57%
0.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneFerm Biotechnology Co Stock analysis

What does GeneFerm Biotechnology Co do? GeneFerm Biotechnology Co., Ltd. generates revenue through the manufacture and sale of health food and supplement products, including fermented products, medicinal mushrooms, lactic acid bacteria products, and fruit and vegetable fermented concentrate products. The company also offers related manufacturing services, health food design, and research and development services. Its primary customers are consumers seeking health-focused dietary supplements, with a focus on fermented and natural health food solutions. The firm targets health-conscious individuals and wellness-oriented markets through its product portfolio. The business model relies on direct sales of its branded health food products, leveraging the growing demand for natural and fermented dietary supplements. The company's R&D services support product innovation, while manufacturing services cater to partners requiring specialized production capabilities. Health food design services further enhance its offerings for clients in the wellness industry. GeneFerm's revenue streams are derived from both product sales and service-based offerings, with a strong emphasis on fermented health food solutions. The company's focus on medicinal mushrooms and lactic acid bacteria products differentiates its market position, appealing to consumers interested in natural health remedies and probiotic benefits. GeneFerm Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

Gross Margin of GeneFerm Biotechnology Co is 28.18 % in 2025.

Gross Margin of GeneFerm Biotechnology Co changed from 18.56 % to 28.18 %, representing a 51.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin GeneFerm Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's GeneFerm Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — GeneFerm Biotechnology Co

All Key Metrics — GeneFerm Biotechnology Co